Salbutamol but not ipratropium fully abolish leukotriene D4 -induced gas exchange abnormalities and induced sputum eosinophilia in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 412s Year: 2003
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Formoterol protects against platelet-activating factor-induced effects in asthma Source: Eur Respir J 2004; 23: 71-75 Year: 2004
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Effect of combined leukotriene, histamine antagonism on the early response to inhaled allergen Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005
Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in the airway remodeling induced by chronic airway inflammation in guinea pigs Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Dose-response of leukotriene CysLT1 -receptor antagonist on nasal lysine-aspirin challenge in patients with aspirin-induced asthma Source: Eur Respir J 2004; 24: Suppl. 48, 585s Year: 2004
The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine Source: Annual Congress 2007 - New drugs for asthma Year: 2007
Inhaled corticosteroids and leukotriene receptor antagonists induce protection against adenosine 5‘monophosphate induced bronchospasm in a synergic fashion Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma Source: Eur Respir J 2004; 24: 226-230 Year: 2004
Fluticasone propionate attenuates platelet-activating factor-induced gas exchange defects in mild asthma Source: Eur Respir J 2002; 19: 872-878 Year: 2002
The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
Cysteinyl leukotrienes and leukotriene B4 in expired breath condensate in patients with chronic asthma treated with montelukast Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 111s Year: 2007
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Anti-inflammatory effects of histamine H1 -receptor antagonist and leukotriene CysLT1 -receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004